Stock DNA
Pharmaceuticals & Biotechnology
CNY 4,813 Million (Small Cap)
17.00
NA
3.64%
0.21
17.22%
2.88
Revenue and Profits:
Net Sales:
419 Million
(Quarterly Results - Sep 2025)
Net Profit:
99 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
5.77%
0%
5.77%
6 Months
13.06%
0%
13.06%
1 Year
32.1%
0%
32.1%
2 Years
51.89%
0%
51.89%
3 Years
43.83%
0%
43.83%
4 Years
121.1%
0%
121.1%
5 Years
157.11%
0%
157.11%
Hunan Fangsheng Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.41%
EBIT Growth (5y)
27.89%
EBIT to Interest (avg)
7.84
Debt to EBITDA (avg)
1.56
Net Debt to Equity (avg)
0.27
Sales to Capital Employed (avg)
0.74
Tax Ratio
11.54%
Dividend Payout Ratio
42.98%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
8.65%
ROE (avg)
12.21%
Valuation key factors
Factor
Value
P/E Ratio
17
Industry P/E
Price to Book Value
2.97
EV to EBIT
20.49
EV to EBITDA
15.32
EV to Capital Employed
2.54
EV to Sales
3.19
PEG Ratio
0.51
Dividend Yield
4.05%
ROCE (Latest)
12.41%
ROE (Latest)
17.14%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
419.10
416.20
0.70%
Operating Profit (PBDIT) excl Other Income
81.90
99.00
-17.27%
Interest
3.50
3.70
-5.41%
Exceptional Items
0.00
0.00
Consolidate Net Profit
98.90
77.80
27.12%
Operating Profit Margin (Excl OI)
195.30%
184.90%
1.04%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 0.70% vs -0.45% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 27.12% vs -12.29% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,761.10
1,613.20
9.17%
Operating Profit (PBDIT) excl Other Income
324.10
243.10
33.32%
Interest
22.10
21.50
2.79%
Exceptional Items
-11.50
-2.40
-379.17%
Consolidate Net Profit
249.80
179.60
39.09%
Operating Profit Margin (Excl OI)
135.80%
100.40%
3.54%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 9.17% vs -9.13% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 39.09% vs -35.09% in Dec 2023
About Hunan Fangsheng Pharmaceutical Co., Ltd. 
Hunan Fangsheng Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






